Corina E. Dutcus

18.0k total citations · 7 hit papers
110 papers, 7.4k citations indexed

About

Corina E. Dutcus is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Corina E. Dutcus has authored 110 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 35 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Corina E. Dutcus's work include Thyroid Cancer Diagnosis and Treatment (35 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Renal cell carcinoma treatment (19 papers). Corina E. Dutcus is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (35 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Renal cell carcinoma treatment (19 papers). Corina E. Dutcus collaborates with scholars based in United States, Japan and United Kingdom. Corina E. Dutcus's co-authors include Matthew H. Taylor, Marcia S. Brose, Makoto Tahara, Naomi Kiyota, Lori J. Wirth, Andrew G. Gianoukakis, Steven I. Sherman, Bruce Robinson, Martin Schlumberger and Vicky Makker and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Corina E. Dutcus

108 papers receiving 7.2k citations

Hit Papers

Lenvatinib versus Placebo... 2011 2026 2016 2021 2015 2020 2011 2015 2019 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
    2015 1.4k citations Martin Schlumberger, Makoto Tahara et al. profile →
  2. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
    2020 850 citations Richard S. Finn, Masafumi Ikeda et al. Journal of Clinical Oncology profile →
  3. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    2011 807 citations Corina E. Dutcus et al. profile →
  4. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
    2015 688 citations Robert J. Motzer, Thomas E. Hutson et al. profile →
  5. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    2019 360 citations Vicky Makker, Drew Rasco et al. profile →
  6. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
    2020 359 citations Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology profile →
  7. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
    2020 306 citations Matthew H. Taylor, Chung‐Han Lee et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Corina E. Dutcus 3.7k 2.4k 1.8k 1.4k 1.3k 110 7.4k
Marcia S. Brose 4.5k 1.2× 2.1k 0.9× 5.1k 2.8× 3.6k 2.5× 1.4k 1.1× 187 11.5k
Christelle de la Fouchardière 7.8k 2.1× 2.8k 1.2× 2.0k 1.1× 1.7k 1.2× 2.8k 2.1× 191 10.9k
Lori J. Wirth 4.3k 1.1× 2.4k 1.0× 4.4k 2.4× 2.0k 1.4× 961 0.7× 260 9.9k
Junming Zhu 4.1k 1.1× 4.3k 1.8× 1.0k 0.6× 1.8k 1.3× 879 0.7× 29 7.3k
Mustafa Özgüroğlu 4.5k 1.2× 7.8k 3.3× 854 0.5× 1.4k 1.0× 2.3k 1.7× 258 10.2k
Milo Frattini 4.9k 1.3× 2.5k 1.0× 274 0.1× 2.6k 1.8× 1.9k 1.4× 109 7.6k
Caroline Caramella 4.6k 1.2× 2.2k 0.9× 318 0.2× 596 0.4× 1.1k 0.9× 137 6.3k
Richard B. Lanman 3.2k 0.8× 3.7k 1.6× 1.8k 1.0× 2.0k 1.4× 4.0k 3.1× 193 8.0k
Paul Bycott 2.9k 0.8× 4.5k 1.9× 518 0.3× 3.7k 2.6× 2.2k 1.7× 51 7.1k
Maria E. Cabanillas 3.8k 1.0× 1.6k 0.7× 6.6k 3.6× 2.4k 1.7× 1.3k 1.0× 215 10.1k

Countries citing papers authored by Corina E. Dutcus

Since Specialization
Citations

This map shows the geographic impact of Corina E. Dutcus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corina E. Dutcus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corina E. Dutcus more than expected).

Fields of papers citing papers by Corina E. Dutcus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corina E. Dutcus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corina E. Dutcus. The network helps show where Corina E. Dutcus may publish in the future.

Co-authorship network of co-authors of Corina E. Dutcus

This figure shows the co-authorship network connecting the top 25 collaborators of Corina E. Dutcus. A scholar is included among the top collaborators of Corina E. Dutcus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corina E. Dutcus. Corina E. Dutcus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arance, Ana, Miguel‐Ángel Berciano‐Guerrero, Jun Guo, et al.. (2025). Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. Annals of Oncology. 36(12). 1535–1546.
2.
3.
Makker, Vicky, Carol Aghajanian, Allen Lee Cohn, et al.. (2023). A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update. Journal of Clinical Oncology. 41(5). 974–979. 25 indexed citations
4.
Yang, James Chih‐Hsin, Baohui Han, Emmanuel de la Mora Jimenez, et al.. (2023). Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. Journal of Thoracic Oncology. 19(6). 941–953. 21 indexed citations
5.
Okusaka, Takuji, Kenji Ikeda, Masatoshi Kudo, et al.. (2021). Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. Journal of Gastroenterology. 56(6). 570–580. 10 indexed citations
6.
Tahara, Makoto, Naomi Kiyota, Ana O. Hoff, et al.. (2021). Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. European Journal of Cancer. 147. 51–57. 37 indexed citations
7.
Taylor, Matthew H., Shunji Takahashi, Jaume Capdevila, et al.. (2021). Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid. 31(8). 1226–1234. 34 indexed citations
8.
Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2021). 796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111. Annals of Oncology. 32. S760–S760. 1 indexed citations
9.
Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2020). Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. Journal of Clinical Oncology. 38(26). 2981–2992. 359 indexed citations breakdown →
10.
11.
Taylor, Matthew H., Chung‐Han Lee, Vicky Makker, et al.. (2020). Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. Journal of Clinical Oncology. 38(11). 1154–1163. 306 indexed citations breakdown →
12.
Grünwald, Viktor, Thomas Powles, Toni K. Choueiri, et al.. (2019). Lenvatinib Plus Everolimus or Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Study Design and Rationale. Future Oncology. 15(9). 929–941. 38 indexed citations
13.
Ikeda, Masafumi, Takashi Sasaki, Chigusa Morizane, et al.. (2017). A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results. Annals of Oncology. 28. v246–v246. 11 indexed citations
14.
Tahara, Makoto, Marcia S. Brose, Lori J. Wirth, et al.. (2017). Impact of duration of dose interruption on the efficacy of lenvatinib (LEN) in a phase 3 sudy in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC). Annals of Oncology. 28. v145–v145. 1 indexed citations
15.
Finn, Richard S., Masatoshi Kudo, Ann‐Lii Cheng, et al.. (2017). Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 28. v617–v617. 11 indexed citations
16.
Lee, Chi‐Hang, Vicky Makker, Matthew H. Taylor, et al.. (2017). A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma. Annals of Oncology. 28. v295–v296. 22 indexed citations
17.
Vogel, Arndt, Shukui Qin, Masatoshi Kudo, et al.. (2017). Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Annals of Oncology. 28. v210–v210. 5 indexed citations
18.
Velcheti, Vamsidhar, Toyoaki Hida, Karen L. Reckamp, et al.. (2016). Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung. Annals of Oncology. 27. vi417–vi417. 32 indexed citations
19.
Taylor, Matthew H., Corina E. Dutcus, Emmett V. Schmidt, et al.. (2016). A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors. Annals of Oncology. 27. vi267–vi267. 23 indexed citations
20.
Robinson, Bruce, Martin Schlumberger, Lori J. Wirth, et al.. (2016). Responses in specific metastases following treatment with lenvatinib (LN): Results from the phase 3 SELECT trial. Annals of Oncology. 27. vi332–vi332. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marcia S. Brose Breakdown of academic impact, for papers by Christelle de la Fouchardière Breakdown of academic impact, for papers by Lori J. Wirth Breakdown of academic impact, for papers by Junming Zhu Breakdown of academic impact, for papers by Mustafa Özgüroğlu Breakdown of academic impact, for papers by Milo Frattini Breakdown of academic impact, for papers by Caroline Caramella Breakdown of academic impact, for papers by Richard B. Lanman Breakdown of academic impact, for papers by Paul Bycott Breakdown of academic impact, for papers by Maria E. Cabanillas
Rankless by CCL
2026